[9/24] WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
COVID-19 ±¹Á¦ ÇöȲ(Global Overview)
Key Points
1. COVID-19 »ç¸ÁÀÚ ¼ö Æò±Õ 7% °¨¼Ò, µ¿³²¾Æ½Ã¾Æ 27% °¨¼Ò
2. ¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½º(VOC) Áö¼ÓÀû È®»ê ¹× Áõ°¡ : µ¨Å¸º¯ÀÌ 36% Áõ°¡
3. 9¿ù COVID-19 ´©Àû È®ÁøÀÚ ÃÑ 2¾ï 30,500¸¸¸í, »ç¸ÁÀÚ 470¸¸¸í ÀÌ»ó
Àü ¼¼°èÀûÀ¸·Î Äڷγª ¹ÙÀÌ·¯½º °¨¿°Àº Áö¼ÓÀûÀ¸·Î È®»êµÇ°í ÀÖÀ¸³ª, »ç¸ÁÀÚ ¼ö´Â ÀüÁÖ¿Í ºñ±³ÇÏ¿© °¨¼Ò Ãß¼¼¿¡ ÀÖ´Ù. 2021³â 9¿ù 24ÀÏ ±âÁØÀ¸·Î º¸°í µÈ Äڷγª¹ÙÀÌ·¯½º °¨¿°Àº Àü ¼¼°è ´©Àû È®ÁøÀÚ¿Í »ç¸ÁÀÚ°¡ °¢°¢ 230,542,888¸í°ú 4,727,498¸íÀ» ³Ñ¾î¼¹´Ù(±×¸² 1). WHO Áö¿ªº° »ç·Ê º¸°í¿¡ ÀÇÇϸé, ¹ÌÁÖ Áö¿ª°ú ÁöÁßÇØ µ¿ºÎ, µ¿³²¾Æ½Ã¾Æ ¹× ¼ÅÂÆò¾ç Áö¿ªÀº ÁÖ°£ ¹ßº´·üÀÌ °¨¼ÒÇÑ °ÍÀ¸·Î º¸°íµÈ ¹Ý¸é, ¾ÆÇÁ¸®Ä«¿Í À¯·´ Áö¿ªÀº ÀüÁÖ¿Í À¯»çÇÑ »ç¸ÁÀÚ ¼ö¸¦ º¸°íÇß´Ù.
COVID-19 ÁÖ°£ »ç¸Á·üÀº ¾ÆÇÁ¸®Ä«¿Í À¯·´ Áö¿ªÀº Áö³ ÁÖ¿Í À¯»çÇÑ »ç·Ê ¼ö¸¦ º¸°íÇÑ ¹Ý¸é, ´Ù¸¥ Áö¿ªÀº ÁÖ°£ »ç·Ê ¹ß»ý·üÀÌ °¨¼ÒÇßÀ¸¸ç ƯÈ÷ µ¿ºÎ ÁöÁßÇØ Áö¿ª°ú µ¿³²¾Æ½Ã¾Æ Áö¿ª¿¡¼ °¢ °¢ 20%, 27%ÀÇ »ó´çÇÑ °¨¼Ò°¡ ³ªÅ¸³µ´Ù(Ç¥ 1).
Ç¥ 1. WHO Áö¿ªº° ½Å±Ô º¸°í ¹× ´©Àû COVID-19 »ç·Ê ¹× »ç¸ÁÀÚ ¼ö( 2021³â 9¿ù 19ÀÏ ±âÁØ)
Ãâó: Weekly epidemiological update on COVID-19 - 21 September 2021
Àü ¼¼°èÀûÀ¸·Î Äڷγª19 »ç¸ÁÀÚ ¼ö´Â ¾à 6¸¸ ¸íÀ¸·Î ÀüÁÖ ´ëºñ 7% °¨¼ÒÇß½À´Ï´Ù. ÀÌ·Î½á ´©Àû »ç¸ÁÀÚ´Â 470¸¸ ¸íÀ» ³Ñ¾î¼¹´Ù. ¾ÆÇÁ¸®Ä«, µ¿ºÎ ÁöÁßÇØ ¹× µ¿³²¾Æ½Ã¾Æ Áö¿ªÀº °ú°Å¿¡ ºñÇØ ÁÖ°£ »ç¸Á·üÀÌ °¨¼ÒÇßÀ¸¸ç, µ¿³²¾Æ½Ã¾Æ Áö¿ªÀÌ °¡Àå Å« ºñÀ² °¨¼Ò(27%)¸¦ º¸°íÇß´Ù. ÀÌ¿¡ ¹ÝÇØ ¼ÅÂÆò¾ç Áö¿ªÀº ÁÖ°£ ½Å±Ô »ç¸ÁÀÚ°¡ 7% Áõ°¡ÇÑ ¹Ý¸é ¹ÌÁÖ¿Í À¯·´ Áö¿ªÀº ÀüÁÖ¿Í ºñ½ÁÇÑ ¼öÁØÀ» º¸¿´´Ù.
±×¸²1 . ±Û·Î¹ú COVID-19 ÇöȲ(Johns Hopkins ´ëÇבּ¸¼Ò ÀÚ·á. 2021³â 9¿ù 24ÀÏ ±âÁØ)
±×¸² 2. COVID-19 ±Û·Î¹ú ÁÖ°£ È®Áø»ç·Ê ¹× »ç¸ÁÀÚ ÃßÀÌ( WHO Region, 2021³â 9¿ù 19ÀÏÀÚ)
±×¸² 3. WHO ±¹°¡ Áö¿ªº° Àα¸ 10¸¸¸í´ç COVID-19 È®ÁøÀÚ(2021³â9¿ù13~19ÀÏÀÚ ±âÁØ)
±×¸² 3¿¡¼ ³ªÅ¸³ª´Â ¹Ù¿Í °°ÀÌ COVID-19 °¨¿° »ç·Ê¿Í »ç¸ÁÀÚ´Â Àα¸ 100,000¸í´ç °¡Àå ³ôÀº ÁÖ°£ ¹ßº´·ü Áö¿ªÀº ÀÌÀü ÁÖ¿Í À¯»çÇÏ°Ô ³ªÅ¸³µ´Ù. ÁÖ°£ ½Å±Ô »ç·Ê°¡ °¡Àå ¸¹ÀÌ º¸°í µÈ ³ª¶ó´Â ¹Ì±¹(1,017,644°Ç, Áö³ ÁÖ¿Í À¯»ç)À̾úÀ¸¸ç, Àεµ(211,242°Ç, 15% °¨¼Ò), ¿µ±¹(203,077°Ç, 21% °¨¼Ò), ÅÍÅ°(183,962°Ç, 16% Áõ°¡), Çʸ®ÇÉ(141,522°Ç, Áö³ÁÖ¿Í À¯»ç) ¼øÀ¸·Î ³ªÅ¸³µ´Ù. ½Å±Ô »ç¸ÁÀÚ°¡ °¡Àå ¸¹Àº ±¹°¡´Â ¹Ì±¹(12,896¸í, 2% Áõ°¡), ·¯½Ã¾Æ(5,469¸í, Áö³ ÁÖ¿Í À¯»ç), ºê¶óÁú(3,727¸í, 17% Áõ°¡), ¸ß½ÃÄÚ(3,689¸í, 20% °¨¼Ò), À̶õ À̽½¶÷ °øȱ¹(2,967¸í, 21% °¨¼Ò) ¼øÀ¸·Î º¸°í µÇ¾ú´Ù.
±×¸² 4. WHO ±¹°¡ Áö¿ªº° Àα¸ 10¸¸¸í´ç COVID-19 »ç¸Á(2021³â9¿ù13~19ÀÏÀÚ ±âÁØ)
º¯ÀÌ ¹ÙÀÌ·¯½º ¾÷µ¥ÀÌÆ®(Special Focus: Update on SARS-CoV-2 Variants of Interest and Variants of Concern)
¾ËÆÄ, º£Å¸, µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º ±¹°¡º° È®»ê Ãß¼¼
Àü ¼¼°èÀûÀ¸·Î ¾ËÆÄ º¯ÀÌÀÇ »ç·Ê´Â 9¿ù 193°³ ±¹¿¡¼ º¸°íµÇ¾î 8¿ù º¸°íµÈ 182°³ ±¹¿¡ ºñÇØ 11°³±¹°¡¿¡ Áõ°¡µÇ¾î º¸°íµÈ ¹Ý¸é, º£Å¸º¯ÀÌ ¹ÙÀÌ·¯½º´Â 8¿ù 132°³±¹¿¡ ÀÌ¿¡ 9¿ù¿¡´Â 142°³±¹¿¡¼ »ç·Ê°¡ º¸°íµÇ¾ú´Ù. °¨¸¶º¯ÀÌ´Â 8¿ù 81°³ ±¹°¡¿¡¼ 9¿ù 96°³±¹À¸·Î Áõ°¡ÇßÀ¸¸ç, µ¨Å¸ º¯ÀÌÀÇ °æ¿ì, 8¿ù 135°³±¹¿¡¼ 9¿ù 185°³±¹À¸·Î 35% Áõ°¡ ÃßÀ̸¦ ³ªÅ¸³»¾ú´Ù.
Ç¥ 2. ¾ËÆĺ¯ÀÌ, º£Å¸º¯ÀÌ, °¨¸¶º¯ÀÌ, µ¨Å¸º¯ÀÌ ¹ÙÀÌ·¯½º °¨¿°ÃßÀÌ(8¿ù~9¿ù)
±¸ºÐ
|
¾ËÆÄ(Alpha)
|
º£Å¸(Beta)
|
°¨¸¶(Gamma)
|
µ¨Å¸(Delta)
|
8¿ù
|
182°³±¹
|
132°³±¹
|
81°³±¹
|
135°³±¹
|
9¿ù
|
193°³±¹
|
142°³±¹
|
96°³±¹
|
183°³±¹
|
Áõ°¡(%)
|
11°³±¹(6.04%)
|
10°³±¹(7.58%)
|
15°³±¹(18.51%)
|
48°³±¹(35.56%)
|
9¿ù ÇöÀç±îÁö °¡Àå ¸¹Àº ³ª¶ó¿¡¼ ÃâÇöÇÏ´Â Äڷγª19 º¯ÀÌ ¹ÙÀÌ·¯½º´Â ¾ËÆÄ º¯ÀÌ(193°³±¹)¿Í µ¨Å¸ º¯ÀÌ(183°³±¹)·Î ³ªÅ¸³µ´Ù. ±Û·Î¹ú Äڷγª 19 ¹ÙÀÌ·¯½º È®»ê°ú °ü·ÃÇÏ¿© º¯ÀÌ ¹ÙÀÌ·¯½º´Â ´Ù¾çÇÑ ÇüÅ·ΠÁö¼ÓÀûÀ¸·Î Áõ°¡ Ãß¼¼¿¡ ÀÖ´Ù.
±×¸² 5. Alpha, Beta, Gamma ¹× Delta º¯ÀÌÃßÀÌ ±¹°¡, ¹× Áö¿ªº°(2021³â9¿ù13~19ÀÏÀÚ ±âÁØ)
¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½º(Variants of Concern, VOC) ÇöȲ
±×¸² 6. WHO°¡ ÁöÁ¤ÇÑ ¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½º(VOC)
¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½º(Variants of Concern, VOI)¶õ?
WHO´Â SARS-CoV-2 º¯ÀÌ, ƯÈ÷ VOI¿¡ ´ëÇÑ Á¤ÀÇ(Definition)¸¦ ¼¼¿ì±â À§ÇØ ¹ÙÀÌ·¯½º °£ ºñ±³ Æò°¡¸¦ ÅëÇÏ¿© Àü ¼¼°è °øÁߺ¸°Ç¿¡ Á߿伺°ú ½É°¢¼º Á¤µµ¸¦ Æò°¡ÇÏ°í, ¾Æ·¡ º¯È Áß Çϳª ÀÌ»ó°ú °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î VOI¸¦ Á¤ÀÇÇÕ´Ï´Ù.
-COVID-19 ¿ªÇÐÀÇ °¨¿°¼º Áõ°¡ ¶Ç´Â À¯ÇØÇÑ º¯È; ¶Ç´Â
-µ¶¼ºÀÇ Áõ°¡ ¶Ç´Â ÀÓ»ó Áúȯ ¹ßÇöÀÇ º¯È; ¶Ç´Â
-°øÁß º¸°Ç ¹× »çȸÀû Á¶Ä¡ ¶Ç´Â ÀÌ¿ë °¡´ÉÇÑ Áø´Ü, ¹é½Å, Ä¡·áÁ¦ÀÇ È¿°ú °¨¼Ò.
°ü½É º¯ÀÌ ¹ÙÀÌ·¯½º(Variants of Interest, VOI)¶õ?
SARS-CoV-2 º¯ÀÌ
°¨¿°¼º, Áúº´ ÁßÁõµµ, ¸é¿ª Å»Ãâ, Áø´Ü ¶Ç´Â Ä¡·á ÀÌÅ»°ú °°Àº ¹ÙÀÌ·¯½º Ư¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµÇ°Å³ª ¾Ë·ÁÁø À¯ÀüÀû º¯È; ±×¸®°í
½Ã°£ÀÌ Áö³²¿¡ µû¶ó È®ÁøÀÚ »ç·Ê Áõ°¡¿Í ÇÔ²² »ó´ëÀû À¯º´·üÀÌ Áõ°¡ÇÏ°í, ¿©·¯ ±¹°¡¿¡¼ ½É°¢ÇÑ Áö¿ª»çȸ ÀüÆÄ ¶Ç´Â ´ÙÁß COVID-19 Ŭ·¯½ºÅ͸¦ À¯¹ßÇÏ´Â °ÍÀ¸·Î È®Àεǰųª, Àü ¼¼°è °øÁß º¸°Ç¿¡ ´ëÇÑ »õ·Î¿î À§ÇèÀ» ½Ã»çÇÏ´Â ±âŸ ¸í¹éÇÑ ¿ªÇÐÀû ¿µÇâÀÌ ÀÖ´Â º¯ÀÌ ¹ÙÀÌ·¯½º.
±×¸² 7. WHO°¡ ÁöÁ¤ÇÑ °ü½É º¯ÀÌ ¹ÙÀÌ·¯½º(VOC)
¼¼°èº¸°Ç±â±¸(WHO)´Â ±¹°¡ ´ç±¹, ±â°ü ¹× ¿¬±¸ÀÚµé°ú Çù·ÂÇÏ¿© SARS-CoV-2ÀÇ º¯ÀÌ ¹ÙÀÌ·¯½º°¡ °¨¿°È®»ê, Áúº´ ½É°¢¼ºÀ» º¯°æÇÏ´ÂÁö¸¦ ¸ð´ÏÅ͸µÇÏ°í ±¹°¡µéÀÇ °øÁߺ¸°ÇÁ¤Ã¥ ¹× »çȸÁ¶Ä¡ (PHSM)¿¡¼ ¹é½Å, Ä¡·á, Áø´Ü È¿°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö Á¤±âÀûÀ¸·Î Æò°¡ÇÏ°í ÀÖ´Ù.
±×¸² 8. ¸ð´ÏÅ͸µÇÏ°í ÀÖ´Â º¯ÀÌ ¹ÙÀÌ·¯½º(Currently designated Variants Under Monitoring)
Ç¥ 3. ¿ì·Á º¯ÀÌ ¹ÙÀÌ·¯½ºÀÇ °¨¿°·Â, Áúº´ÁßÁõµµ, Àç°¨¿° À§Çè, Áø´Ü¿µÇâ
Ç¥3¿¡ ³ªÅ¸³ ¹Ù¿Í °°ÀÌ ¾ËÆÄ, º£Å¸, °¨¸¶, µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º´Â ¸ðµÎ °øÅëÀûÀ¸·Î °¨¿°·ÂÀÌ Áõ°¡ÇÑ °ÍÀÌ Æ¯Â¡À¸·Î ³ªÅ¸³´Ù. ƯÈ÷ µ¨Å¸º¯ÀÌ ¹ÙÀÌ·¯½º´Â ÀüÆÄ·ÂÀÌ Áõ°¡ÇÒ »Ó¸¸ ¾Æ´Ï¶ó 2Â÷ °ø°ÝÀ²µµ ³ô´Ù´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ¾ËÆĺ¯ÀÌ¿Í °¨¸¶ ¹× µ¨Å¸ º¯ÀÌ´Â ÀÔ¿ø À§ÇèÀ» ³ôÀÌ°í Áúº´ÁßÁõµµ Áõ°¡ ¹× »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃŲ´Ù. ƯÈ÷ º£Å¸º¯ÀÌ¿Í µ¨Å¸º¯ÀÌ´Â Áß¼º È°¼ºÀ» °¨¼Ò½ÃÅ°°í ¸é¿ª¹ÝÀÀÀ» Á¦ÇѽÃÅ°´Â Ư¡ÀÌ ÀÖ´Ù.
Ç¥ 4. ±¹°¡ ¹× Áö¿ªº° ¿ì·Á º¯ÀÌ(Variants of Concern) ÇöȲ(WHO, 2021³â 9¿ù 21ÀÏ º¸°í)
[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
CDC: Äڷγª19 ¹é½Å- ÀÔ¿øÀ§Çè 10¹è ¿¹¹æ È¿°ú
¹Ì±¹Áúº´ÅëÁ¦¿¹¹æ¼¾ÅÍ(CDC)°¡ ÃÖ±ÙÀÇ ¿¬±¸°á°ú¸¦ ¹ÙÅÁÀ¸·Î ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19) ¹é½ÅÀÇ È¿°ú´Â ÀÔ¿ø À§ÇèÀ» 10ºÐÀÇ 1·Î °¨¼Ò½ÃÅ°°í, ¹ÌÁ¢Á¾ÀÚ°¡ Äڷγª19 ¹ÙÀÌ·¯½º °¨¿°ÀÌ µÉ °æ¿ì »ç¸ÁÀ§ÇèÀº 11¹è ÀÌ»ó ³ô°Ô ³ªÅ¸³²À» º¸°íÇß´Ù[»ó¼¼º¸±â].
±×¸² 1. COVID-19·Î ÀÔ¿øÇÑ 18¼¼ÀÌ»ó Å𿪠±ºÀο¡ ´ëÇÑ SARS-CoV-2 Àüü °Ô³ð½ÃÄö½Ì °èÅë ºÐ¼®°á°ú. ÀçÇⱺÀθ޵ðÄü¾ÅÍ(Veterans Affairs Medical Centers, VAMC)ÀÚ·á, (±â°£ 2021³â 2¿ù 1ÀÏ–8¿ù 6ÀÏ). [Ãâó CDC: Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalization — Five Veterans Affairs Medical Centers, United States]
¾á¼¾¹é½Å ´ÜÀÏ Á¢Á¾- 6°³¿ù ÈÄ ºÎ½ºÅÍ ¼¦, Ç×ü 9¹è Áõ°¡
Johnson & Johnson booster shot prompts large increase in immune response, company says
¹Ì±¹ Á¸½¼¾ØµåÁ¸½¼ÀÇ ¾á¼¾ ¹é½ÅÀÌ ºÎ½ºÅͼ¦À» ¸ÂÀ¸¸é Ç×ü ¼öÁØÀÌ Å©°Ô ³ô¾ÆÁø´Ù´Â ¿¬±¸ °á°ú°¡ ³ª¿Ô´Ù. ¹Ì±¹ Á¸½¼¾ØµåÁ¸½¼(J&J) ¹é½ÅÀº ¿ø·¡ ÇÑ ¹ø¸¸ ¸Â´Â ¾á¼¾ ¹é½ÅÁ¢Á¾À» ºÎ½ºÅÍ ¼¦À» ¸ÂÀ¸¸é Ç×ü ¼öÁØÀÌ Å©°Ô ³ô¾ÆÁö´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù°í ¹àÇû´Ù[»ó¼¼º¸±â].
¶÷´Ùº¯ÀÌ(C.37) Á¤º¸- ÇöÀç±îÁö ¾Ë·ÁÁø »çÇ×µé
SARS-CoV-2 lambda variant
SARS-CoV-2 ¶÷´Ù º¯ÀÌ(C.37)´Â Æä·ç¿¡¼ óÀ½ È®ÀεǾú´Ù. ÀÌÈÄ ³²¾Æ¸Þ¸®Ä«¿Í ¹Ì±¹ÀÇ ´Ù¸¥ Áö¿ªÀ¸·Î ºü¸£°Ô È®»êµÇ°í ÀÖ´Ù. C.37·Îµµ ¾Ë·ÁÁø ¶÷´Ù º¯ÀÌ°¡ ÇöÀç ¿µ±¹°ú ¹Ì±¹¿¡¼ Áö¹èÀûÀÎ µ¨Å¸º¯À̺¸´Ù ´õ °¨¿°µÉ ¼ö ÀÖ´Ù°í °æ°íÇß´Ù. ¹ÙÀÌ·¯½º ¼ö¿ëü °áÇÕ µµ¸ÞÀÎ(receptor-binding domain, RBD)À» Æ÷ÇÔÇÏ´Â SARS-CoV-2ÀÇ ½ºÆÄÀÌÅ© ´Ü¹éÁúÀº ¼÷ÁÖ¼¼Æ÷ ¾ÈÁö¿ÀÅٽŠÀüȯ È¿¼Ò 2 (ACE2) ¼ö¿ëü¿¡ °áÇÕÇÑ´Ù. ½ºÆÄÀÌÅ© ´Ü¹éÁú°ú RBD ¸ðµÎÀÇ µ¹¿¬º¯ÀÌ´Â Ç×ü¸Å°³ÁßÈ ¹× °¨¿°¿¡ ´ëÇÑ »õ·Î¿î SARS-CoV-2 º¯ÀÌüÀÇ ³»¼º °È°¡ ÇÙ½É À̽´ÀÌ´Ù[»ó¼¼º¸±â].
¶÷´Ù º¯ÀÌü(Ãâó : manaemedia / Shutterstock.com)
¸ð´õ³ª ¹é½Å È¿°ú 90%ÀÌ»ó, 6°³¿ù Áö¼Ó¼º, µ¨Å¸º¯ÀÌ ¿¹¹æÈ¿°ú
(Moderna COVID-19 Vaccine Overview and Safety)
Moderna ¹é½ÅÀº ¼¼Æ÷¿¡ ¾à°£ÀÇ À¯Àü Äڵ带 Àü´ÞÇÏ´Â ±â¼úÀÎ mRNA ¶Ç´Â ¸Þ½ÅÀú RNA¸¦ »ç¿ëÇÏ¿© »ý¼ºµÈ´Ù. ÃÖ±Ù CDC ¿¬±¸¿¡ µû¸£¸é ½ÇÁ¦ ȯ°æ¿¡¼ ¿ÏÀü ¿¹¹æÁ¢Á¾(µÎ ¹ø° Á¢Á¾ ÈÄ ÃÖ¼Ò 14ÀÏ) ½Ã ¹é½ÅÀÇ È¿°ú°¡ 90% ÀÌ»óÀÎ °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç ¿¹¹æÈ¿°ú´Â Á¢Á¾ ¿Ï·á ÈÄ ¾à 6°³¿ù Áö¼ÓµÇ´Â °ÍÀ¸·Î º¸°íµÈ´Ù. [»ó¼¼º¸±â]
µ¨Å¸º¯ÀÌ(B.1.617.2) ÁÖ¿ä Áõ»ó ¹× ±Û·Î¹ú È®»êÇöȲ
(Delta Variant’s Sign & Symptoms)
WHO´Â ÃÖ±Ù Äڷγª19 ÇöȲ º¸°í¿¡¼ ¿ì·ÁµÇ´Â º¯ÀÌ(VOC)ÀÇ Ç¥ÇöÇü Ư¼º(ÀüÆļº, Áúº´½É°¢µµ, Àç°¨¿° À§Çè, Áø´Ü ¹× ¹é½Å È¿´É ¿µÇâ)°ú °ü·ÃµÈ »õ·Î¿î ¾÷µ¥ÀÌÆ®¸¦ ¹ßÇ¥Çß´Ù. ¿©±â¿¡´Â Äڷγª º¯ÀÌ ¹ÙÀÌ·¯½ºÀÇ Áö¸®Àû ºÐÆ÷¸¦ Æ÷ÇÔÇÏ¿© VOCs ¹× º¯ÀÌ ºÐ·ù, ¸ð´ÏÅ͸µ ÁßÀÎ ¾Æ¹Ì³ë»ê º¯È ¹× ±âŸ º¯ÀÌ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ³»¿ëÀ» ¹ßÇ¥Çß´Ù. [»ó¼¼º¸±â]
Äڷγª19 ¹é½Å È¥ÇÕ-±³Â÷ Á¢Á¾ È¿°ú¿Í ºÎ½ºÅͼ¦?
(Mix-and-Match Approach to Covid Vaccines)
-¾Æ½ºÆ®¶óÁ¦³×Ä« & ÈÀÌÀÚ ±³Â÷Á¢Á¾ È¿°ú-
Covid ¹é½Å¿¡ ´ëÇÑ ¹Í½º ¾Ø ¸ÅÄ¡ ¹æ½Ä (1Â÷ ¹× 2Â÷ Á¢Á¾¿¡ ¼·Î ´Ù¸¥ ºê·£µåÀÇ ¹é½Å »ç¿ë)Àº Äڷγª ÆÒµ¥¹Í ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ È¿°úÀûÀÎ ¿¹¹æÀÌ µÉ ¼ö ÀÖÀ½ÀÌ ¿µ±¹ÀÇ ÇÑ ¿¬±¸¿¡¼ ¹àÇôÁ³´Ù. Äڷγª19 ¹é½Å È¥ÇÕ-±³Â÷ Á¢Á¾ ¿¬±¸°á°ú(Mix-and-Match Approach to Covid Vaccines) [»ó¼¼º¸±â]
“µ¨Å¸ Ç÷¯½º(Delta Plus)” º¯ÀÌ ¹é½ÅÈ¿°ú?
'Delta' Variant Of COVID-19 Mutates Into 'Delta Plus'
Àεµ¿¡¼ óÀ½ ¹ß»ýÇÑ ‘µ¨Å¸’(Delta) º¯ÀÌ ¹ÙÀÌ·¯½ºÀÇ Àü ¼¼°è È®»êÀÌ °Å¼¼Áö°í ÀÖ´Ù. µ¨Å¸º¯ÀÌ´Â Áö³ÇØ 10¿ù Àεµ¿¡¼ óÀ½ º¸°í µÇ¾úÀ¸³ª, ¿µ±¹¿¡¼ óÀ½ ¹ß°ßµÈ ‘¾ËÆÄ’( alpha) ¹öÀü°ú ºñ±³ÇÏ¿© 50ÆÛ¼¾Æ® ÀÌ»óÀÇ °ÇÑ °¨¿°·ÂÀ» ³ªÅ¸³»°í ÀÖ´Ù. ƯÈ÷ µ¨Å¸ º¯ÀÌ ¹ÙÀÌ·¯½º¿Í ºñ±³ÇÏ¸é ‘µ¨Å¸ Ç÷¯½º’ µ¹¿¬º¯ÀÌ´Â ÀüÆÄ·Â »Ó¸¸ ¾Æ´Ï¶ó ¹é½Å¿¡ ´ëÇÑ ³»¼ºÀÌ ´õ °ÇÑ °ÍÀ¸·Î Æò°¡¹Þ°í ÀÖÀ¸¸ç, ‘µ¨Å¸ Ç÷¯½º º¯ÀÌ’°¡ ÀÌ¹Ì Àεµ 3°³ Áö¿ªÀ» Æ÷ÇÔÇÏ¿© ¹Ì±¹, ¿µ±¹, Áß±¹, ÀϺ»±îÁö °¨¿°ÀÌ È®»êµÇ¾î ¹ß»ýÇÏ°í ÀÖ´Ù. [»ó¼¼º¸±â]
¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½Å 3»ó ÀÓ»ó°á°ú(Phase III, Clinical Trial) ¹ßÇ¥ (Latest results put Oxford–AstraZeneca COVID vaccine back on track)
¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½Å °³¹ß»ç´Â ÃÖ±Ù 3¿ù 26ÀÏÀÚ·Î ÇÙ½ÉÀ̵Ǵ ÀÓ»ó 3»ó(Phase III Clinical Trial) ¿¬±¸°á°ú¿¡¼ 76%ÀÇ Äڷγª-19¹é½Å ¿¹¹æÈ¿°ú °á°ú¸¦ ¹ßÇ¥Çß´Ù. À¯·´ÀǾàǰû(EMA)Àº ¹é½ÅÀÇ Ç°Áú, ¾ÈÀü¼º ¹× È¿´É¿¡ ´ëÇÑ µ¥ÀÌÅÍ Æò°¡¸¦ ÅëÇØ, 18¼¼ÀÌ»ó ¼ºÀÎÀ» ´ë»óÀ¸·Î ¿Á½ºÆ÷µå-¾Æ½ºÆ®¶óÁ¦³×Ä« ¹é½ÅÁ¢Á¾ ½ÂÀÎÀ» Çã¿ëÇÔÀ» ¹ßÇ¥Çß´Ù. [»ó¼¼º¸±â]
COVID-19 ¼¼°¡Áö Áø´Ü°Ë»ç ºñ±³ : ºñÀεεµ¸» PCR, Ÿ¾× PCR, ½Å¼ÓÇ׿ø°Ë»ç - Three COVID-19 Diagnostic Tests in Korea -
"ºñÀεεµ¸» PCR→Ÿ¾× PCR→½Å¼ÓÇ׿ø°Ë»ç ¼ø ±ÇÀå…°Ë»ç°á°ú Á¤È®µµ Â÷ÀÌ"
¿ì¸®³ª¶ó¿¡¼ ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â ¼¼°¡Áö Äڷγª19 °Ë»çÁø´Ü¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù. Áúº´°ü¸®Ã» Á߾ӹ濪´ëÃ¥º»ºÎ´Â Äڷγª19 Á¤·Êºê¸®Çο¡¼ ¼¼ °¡Áö Äڷγª19 °Ë»ç¹ý¿¡ ´ëÇØ ¼³¸íÇÏ¸é¼ ¹Î°¨µµ(Sensitivity)¿Í ƯÀ̵µ(specificity)¸¦ °ø°³Çß´Ù. Ç¥ÁØ°Ë»ç¹ýÀÎ ºñÀεεµ¸» PCR(½Ç½Ã°£ ¿ªÀü»ç ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ, rRT-PCR, qRT-PCR)Àº ¹Î°¨µµ 98% ÀÌ»ó, ƯÀ̵µ 100%À̸ç Ÿ¾× PCRÀº ¹Î°¨µµ 92%, ƯÀ̵µ 100%´Ù. ¹Ý¸é, ½Å¼ÓÇ׿ø°Ë»ç¹ýÀº ¹Î°¨µµ 90%, ƯÀ̵µ 96%·Î ¼¼ °¡Áö °Ë»ç¹ý Áß °¡Àå ³·´Ù[»ó¼¼º¸±â]
³ëÈÀÇ °üÁ¡¿¡¼ COVID-19 ÀÓ»óÀû ¾ç»ó - COVID-19 ³ëÀΠȯÀÚÀÇ ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·Â
Understanding the Clinical Features of Coronavirus Disease 2019 From the Perspective of Aging: A Systematic Review and Meta-Analysis
-High Inflammatory State and Low Immune Defense of the Aging Patients With COVID-19-
ÀÓ»óÁú¹® :
³ëÀε鿡°Ô Äڷγª19 °¨¿°ÀÌ ´õ¿í À§Çè°ÍÀº ÀþÀº Ãþ¿¡ ºñÇÏ¿© ³·Àº ¸é¿ª¹æ¾î ´É·ÂÀ̳ª ³ôÀº ¿°Áõ»óÅÂ¿Í °ü·ÃÀÌ ÀÖ½À´Ï±î?
¿¬±¸´äº¯ :
³ëÀÎÃþ ȯÀÚÀÇ Ç÷¾×°Ë»ç°á°ú ÀþÀº Ãþ¿¡ ºñÇÏ¿© ¹éÇ÷±¸ÀÇ ³ôÀº °¡º¯¼ºÀ» ³ªÅ¸³»¾ú´Ù. COVID-19 ³ëÀÎȯÀÚÀÇ ½ÇÇè½Ç °á°ú ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·ÂÀ¸·Î COVID-19 ³ëÀÎ Àα¸¿¡¼ COVID-19·Î ÀÎÇÑ Ãë¾à¼º°ú ºÒ¾ÈÁ¤ÇÑ »óŸ¦ ³ªÅ¸³»¾ú´Ù. Ç÷¾×°Ë»ç °á°ú C- ¹ÝÀÀ¼º ´Ü¹éÁú, ÇÁ·Î Ä®½ÃÅä´Ñ ¹× ÀÎÅÍ·çŲ -6 (C-reactive protein, procalcitonin, and interleukin-6) Åë°è ºÐ¼®À» ¼öÇàÇÏ¿© ³ëÀΠȯÀÚÀÇ ¿°Áõ ¹× ¸é¿ª ¹ÝÀÀÀ» Ãß·ÐÇÏ°í Ç÷¼ÒÆÇ°ú D-dimer¸¦ °è»êÇÏ¿© ³ëÀΠȯÀÚÀÇ ÀÀ°í±â´ÉÀ» È®ÀÎÇÏ¿´´Ù[»ó¼¼º¸±â]
[NEJM] ÈÀÌÀÚ & ¹ÙÀÌ¿À¿£Å×Å© COVID-19 ¹é½Å(Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine) ÀÓ»ó°á°ú ¹× ºÎÀÛ¿ë ¹ßÇ¥
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
¹Ì±¹ Á¦¾àȸ»ç ÈÀÌÀÚ¿Í µ¶ÀÏ »ý¸í°øÇбâ¾÷ ¹ÙÀÌ¿À¿£Å×Å©(BioNTech SE)´Â mRNA ±â¹Ý Äڷγª19 ¹é½Å Èĺ¸¹°Áú ‘BNT162b2’ÀÇ ÀÓ»ó 3»ó ½ÃÇè¿¡¼ µµÃâµÈ ¾ÈÀü¼º ¹× È¿´É¼º °á°ú¿¡ ´ëÇØ ÀÇÇÐ ÇмúÁö ‘´º À×±Û·£µå Àú³Î ¿Àºê ¸Þµð½¼’(NEJM)¿¡ °ÔÀçµÆ´Ù°í 10ÀÏÀÚ·Î ¹ßÇ¥Çß´Ù[»ó¼¼º¸±â].
COVID-19 ȯÀÚÀÇ Ä¡¸íÀ², ÀÓ»óƯ¼º, Åð¿øÀ²
COVID?19 patients' clinical characteristics, discharge rate, and fatality rate of meta?analysis
ÀÌ ¿¬±¸´Â COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î COVID-10ȯÀÚÀÇ Åð¿ø·ü ¹× »ç¸Á·üÀ» ºÐ¼®ÇϱâÀ§ÇØ 2019 ³â 12 ¿ùºÎÅÍ 2020 ³â 2 ¿ù±îÁö COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅÍ´Â 4 °³ÀÇ µ¥ÀÌÅͺ£À̽º¿¡¼ °Ë»öÇÏ¿´´Ù. COVID-19 ȯÀÚÀÇ ÀÓ»ó Áõ»ó°ú °Ë»ç½Ç °á°ú¸¦ Åë°èÀûÀ¸·Î ºÐ¼®ÇÏ°í ´ÜÀÏ ±º ¸ÞŸ ºÐ¼®À¸·Î Åð¿øÀ² °ú »ç¸Á·üÀ» ¼³¸íÇß´Ù. 10°³ÀÇ ¹®Çå¿¡¼ 1994 ³â ȯÀÚÀÇ ÀÌ¿ë °¡´ÉÇÑ µ¥ÀÌÅÍ°¡ ¿¬±¸¿¡ Æ÷ÇԵǾú´Ù. [»ó¼¼º¸±â]
Source: Johns Hopkins University CSSE COVID 19 Data-Last Updated 8 December, 21:06 (London time)
[JAMA] COVID-19 °¨¿°µÈ »ê¸ð¿¡¼ ÅÂ¾î³ ½Å»ý¾Æ´Â COVID-19 Ç×üº¸À¯ (Antibodies in Infants Born to Mothers With COVID-19 Pneumonia)
JAMA¿¡ ¹ßÇ¥µÈ À̹ø ¿¬±¸´Â COVID-19°¡ È®Áø µÈ 6 ¸íÀÇ ÀÓ»êºÎ¿Í ½Å»ý¾Æ¿¡°Ô »õ·Î¿î Ç÷ûÇÐÀû ±âÁØÀ¸·Î ½Å»ý¾Æ °¨¿°¿¡ ´ëÇÑ º¸´Ù ÀÚ¼¼ÇÑ Á¶»ç ±âÁØÀ» Àû¿ëÇؼ COVID-19¿¡ °¨¿°µÈ ¸ð¼º¿¡°Ô¼ ÅÂ¾î³ ½Å»ý¾ÆÀÇ COVID-19 Ç×ü º¸À¯¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼öÇàÇÏ¿´´Ù. [»ó¼¼º¸±â]
COVID-19 Vaccines ºñ±³: ÈÀÌÀÚ(Pfizer & BioNTech), ¸ð´õ³ª(Moderna) & ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)
¹Ì±¹ ÈÀÌÀÚ¿Í µ¶ÀÎ ¹ÙÀÌ¿À¿£Å×Å©(Pfizer & BioNTech) °³¹ßÇÑ COVID-19 ¹é½Å°ú ¹Ì±¹ ¸ð´õ³ª(Moderna) Á¦¾àȸ»çÀÇ ¹é½Å °³¹ß ¹ßÇ¥¿¡ À̾î, ¿µ±¹°è ´Ù±¹Àû Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)´Â 23ÀÏ Èıâ ÀÓ»ó½ÃÇè¿¡¼ 90% È¿°ú°¡ ÀÖ´Â °·ÂÇÑ COVID-19 ¹é½ÅÀÇ ÀÓ»ó½ÃÇè °á°ú¸¦ ÀÕ´Þ¾Æ ¹ßÇ¥Çß´Ù. ÀÌÁ¦ Àü¼¼°è´Â Äڷγª19 °¨¿°À» µåµð¾î ³¡³¾ ¹é½ÅÀÌ °³¹ßµÈ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ´Ù. [»ó¼¼º¸±â]
NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ
¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)
ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷ȵµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]
[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]
COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼º¸±â]
NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ
ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]
Ç¥ 5) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü COVID -19 ÃֽŠÁ¤º¸ ¹Ù·Î°¡±â
±¹³» ¹× ±¹¿Ü ±â°ü
|
¸µ Å©
|
Áúº´°ü¸®Ã» Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ
|
https://kdca.go.kr/index.es?sid=a2
|
¹Ì±¹ CDC Coronavirus Disease (COVID-19)
|
https://www.cdc.gov/coronavirus/index.html
|
¼¼°èº¸°Ç±â±¸(WHO) Coronavirus (COVID-19) Epidemical Update
|
https://www.who.int/health-topics/coronavirus#tab=tab_1
|
Ç¥ 6) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Á¦°ø
* º» ³»¿ëÀº MedRIC (www.medric.or.kr)ÀÇ ¿¬±¸µ¿Çâ¿¡¼ ¼ºñ½ºµÇ´Â ³»¿ëÀÔ´Ï´Ù.